In this review, we trace the history of the early-generation of urine BC biomarkers identified in the telomerase pathway, discuss the limitations of the detection of related assays, and highlight the potential of transcription-activating mutations in the promoter of the TERT gene detected in the urine as promising simple non-invasive biomarkers for the detection of BC and surveillance for its relapse. Here, TERT is linked to breast cancer.